Jack Nguyen

This inventor holds 4 USPTO granted patents, plus 3 CIPO patents and 4 EPO patents. Top assignee: Catalyst Biosciences, Inc.. Active years: 2011-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jack Nguyen. Retrieved from https://idiyas.com/inventor/jack-nguyen-3pn1l77a

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4

% Patents Active = 50.0

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 2)

Average Co-Inventor Count = 2.3

ph-index = 4

Forward Citations = 33(Granted Patents)

Location History:

South San Franciso, CA (US) (2011 - 2013)
Oakland, CA (US) (2016 - 2017)

Company Filing History:

4 out of 26

Catalyst Biosciences, Inc.

patents

Years Active: 2011-2017

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9795655 - Modified MT-SP1 proteases that inhibit complement activation (2017-10-24),

2. 9359598 - Mutant MT-SP1 proteases with altered substrate specificity or activity (2016-06-07),

3. 8445245 - Mutant MT-SP1 proteases with altered substrate specificity or activity (2013-05-21),

4. 7939304 - Mutant MT-SP1 proteases with altered substrate specificity or activity (2011-05-10),

Title: Jack Nguyen: Innovator in Complement System Modulation

Introduction

Jack Nguyen is a prominent inventor based in Oakland, CA, known for his significant contributions to the field of biochemistry and therapeutic innovations. With a total of four patents to his name, Nguyen has focused on developing methods and compounds that modulate the complement system, which plays a crucial role in immune response and inflammation.

Latest Patents

Nguyen's latest patents include groundbreaking work on modified MT-SP1 proteases that inhibit complement activation. These compounds are designed to modulate the complement system, providing therapeutic options for various conditions. Specifically, the compounds that inhibit complement activation can be utilized in the treatment of ischemic and reperfusion disorders, such as myocardial infarction and stroke, as well as autoimmune diseases, inflammatory diseases, and neurodegenerative disorders like Alzheimer's Disease. Additionally, he has developed mutant MT-SP1 proteases with altered substrate specificity or activity, which can be employed to treat human diseases, including cancer, by cleaving VEGF or VEGFR at specific substrate sequences.

Career Highlights

Nguyen's career is marked by his innovative research and development efforts at Catalyst Biosciences, Inc. His work has not only advanced scientific understanding but has also paved the way for new therapeutic strategies in treating complex diseases. His dedication to research and innovation has made him a valuable asset in the field of biochemistry.

Collaborations

Profile summary based on public USPTO records.